Overview

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending IV dose administrations in subjects with prodromal or mild Alzheimer's disease (AD) (Part 2).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC